Hematopoiesis News 10.01 January 15, 2019 | |
| |
TOP STORYLentiviral vector transduction of scurfy HSCs restored development of functional FoxP3+ regulatory T cells that suppress T cell proliferation in vitro and rescue the scurfy autoimmune phenotype in vivo. [Cell Stem Cell] Abstract | Press Release | Graphical Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)The Splicing Factor RBM25 Controls MYC Activity in Acute Myeloid Leukemia In multiple human leukemic cell lines, knockdown of RBM25 promoted proliferation and decreased apoptosis. Mechanistically, researchers showed that RBM25 controlled the splicing of key genes, including those encoding the apoptotic regulator BCL-X and the MYC inhibitor BIN1. [Nat Commun] Full Article Downregulation of the symmetric dimethylation of H4R3 (H4R3sme2) by protein arginine methyltransferase 5 (PRMT5) silencing induced pediatric B-cell precursor-acute lymphoblastic leukemia cell differentiation from the pre-B to immature B stage, whereas overexpressed PRMT5 with enhanced H4R3sme2 promoted human mature B cells to dedifferentiate back to the pre-B II/immature B stages in vitro. [Clin Cancer Res] Abstract The Transcriptional Regulator FUBP1 Influences Disease Outcome in Murine and Human Myeloid Leukemia In murine models of chronic (CML) and acute myeloid leukemia (AML) induced by BCR-ABL1 and MLL-AF9, respectively, knockdown of far upstream element binding protein 1 (FUBP1) resulted in prolonged survival, decreased numbers of CML progenitor cells, decreased cell cycle activity and increased apoptosis. [Leukemia] Abstract LEF-1 Drives Aberrant Β-Catenin Nuclear Localization in Myeloid Leukemia Cells LEF-1 knockdown perturbed β-catenin nuclear-localization and transcriptional activation in Wnt-responsive cells. Conversely, LEF-1 overexpression was able to promote both nuclear-localization and β-catenin-dependent transcriptional responses in previously Wnt-unresponsive cells. [Haematologica] Abstract Treatment with venetoclax increased MCL1 protein levels, but cotreatment with ABBV-075 reduced MCL1 and Bcl-xL levels. ABBV-075 cotreatment synergistically induced apoptosis with venetoclax or A-1210477 in patient-derived, CD34+ AML cells. [Blood Cancer J] Full Article Both primed HSCs (pHSCs) and reserve HSCs (rHSCs) supported long-term hematopoiesis in homeostasis; however, pHSCs were sensitive but rHSCs were resistant to chemotherapy. Ablation of N-cadherin+ (N-cad+) niche cells or deletion of SCF from N-cad+ niche cells impaired rHSC maintenance during homeostasis and regeneration. [Cell Rep] Full Article | Press Release | Graphical Abstract Scientists found that erythropoietin (EPO) suppressed p53-dependent apoptosis induced by genotoxic and non-genotoxic agents and induced a senescence-like state in myeloid leukemia cells. EPO interfered with stress-dependent Mdm2 downregulation and led to the destabilization of p53 protein. [Cell Death Dis] Full Article Researchers investigated the ability of acute myeloid leukemia stem cells to survive and proliferate in suspension cultures in the presence of exogenous mediators but without supporting non-leukemic cells. [Cancers] Abstract | Download Full Article CLINICAL RESEARCHPatients were randomized to receive HSC transplantation along with cyclophosphamide and antithymocyte globulin or disease-modifying therapy (DMT) of higher efficacy or a different class than DMT taken during the previous year. [JAMA] Abstract | Editorial Researchers conducted a retrospective comparison of three different preparative regimens used for allogeneic hematopoietic cell transplant for multiple myeloma at an institution in recent clinical trials: busulfan/fludarabine, fludarabine/melphalan 100mg/m2 (FM100), and FM140. [Biol Blood Marrow Transplant] Abstract Subscribe to one of our other 19 science newsletters such as Cord Blood News & Cell Therapy News. | |
| |
REVIEWST Cell Receptor-Engineered T Cells for Leukemia Immunotherapy Clinical trials involving chimeric antigen receptor-engineered T cells have been a major breakthrough and are a novel therapy for leukemia. The authors present a review of the current status of anti-leukemia immunotherapy using leukemia antigen-specific T cell receptor-engineered T cells. [Cancer Cell Int] Full Article Visit our reviews page to see a complete list of reviews in the hematopoiesis research field. | |
| |
SCIENCE NEWSCorvus Pharmaceuticals, Inc. announced data from a preclinical study of CPI-818, its investigational small molecule T-cell signaling pathway inhibitor. [Press release from Corvus Pharmaceuticals, Inc. discussing research presented at the 11th Annual T-Cell Lymphoma Forum, La Jolla] Press Release | |
| |
INDUSTRY NEWSBeiGene Receives U.S. FDA Breakthrough Therapy Designation for Zanubrutinib in Mantle Cell Lymphoma BeiGene, Ltd. announced that the FDA has granted Breakthrough Therapy designation for its investigational Bruton’s tyrosine kinase inhibitor, zanubrutinib, for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy. [BeiGene, Ltd.] Press Release Rafael Pharmaceuticals, Inc. announced that the European Medicines Agency (EMA) has granted orphan drug designation to devimistat, the dompany’s lead Altered Metabolism Directed drug candidate, for the treatment of older patients with relapsed or refractory AML. [Rafael Pharmaceuticals, Inc. (GlobeNewswire, Inc.)] Press Release miRagen Therapeutics, Inc. announced data from its Phase I clinical trial evaluating the safety, tolerability and efficacy of cobomarsen, an inhibitor of microRNA-155, in cutaneous T-cell lymphoma and in adult T-cell leukemia/lymphoma. [miRagen Therapeutics, Inc.] Press Release Moleculin Announces Patient Recruitment Begins in Annamycin Clinical Trial in Poland Moleculin Biotech, Inc. announced it has begun in Poland recruiting patients in the company’s second clinical trial to study annamycin for the treatment of relapsed and refractory adults with acute myeloid leukemia. [Moleculin Biotech, Inc.] Press Release Cellular Biomedicine Group Inc. announced the initiation of patient recruitment to support the study of anti-BCMA CAR-T therapy targeting relapsed and refractory MM in China. [Cellular Biomedicine Group Inc.] Press Release | |
| |
POLICY NEWSIf the Shutdown Drags on at FDA, It Will Put Anticipated New Treatments in Jeopardy The government shutdown could soon jeopardize highly anticipated new drugs from Janssen, Sanofi and Novartis for depression, diabetes and multiple sclerosis, as well as a host of other potential new therapies, according to a STAT analysis of upcoming regulatory decision dates. [STAT News] Editorial Serbia Is Rethinking Science — But the Reforms Could Cost Hundreds of Jobs The government says that it is keen to revitalize and invest more in its cash-starved research system, which has an annual budget of about €100 million (US$115 million) and last put out a grant call nearly a decade ago. But some scientists say that the reforms, although badly needed, will lead to hundreds of university researchers losing their jobs. [Nature News] Editorial
| |
EVENTSNEW 2019 Highlights of ASH® in Asia-Pacific Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESResearch Technologist – Hematopoietic (STEMCELL Technologies Inc.) Assistant Professor – Sarcoma & Skeletal-Related Malignancies (UC Davis School of Medicine) Research Fellow – Myeloid Leukemia (University College of London) Postdoctoral Scholar – Cancer Development (University of Southern California) Postdoctoral Position – Regenerative Medicine, Stem Cells and Bioengineering (Igenomix Foundation) Assistant Project Scientist – Hematology and Oncology (University of California, Davis) Research Scientist – Hematological Malignancies (MD Anderson Cancer Center) Faculty Positions – Hematology and Oncology (UC Davis) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Hematopoiesis News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|